Crinetics Pharmaceuticals, Inc. Share Price & Technical Analysis
CRNX · $36.80 (-0.78%)
Healthcare / Biotechnology
$36.80
-0.78%
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromeg…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
-5% return in May, 2% avg return in past 3 year May month.
-19% return in 2026, 44% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 7% | -17% | -10% | 6% | -5% | – | – | – | – | – | – | – | -19% |
| 25 | -22% | -9% | -7% | 0% | -8% | -6% | -1% | 10% | 34% | 5% | 5% | 4% | 5% |
| 24 | 4% | 11% | 13% | -6% | 1% | 0% | 18% | 0% | -4% | 10% | 1% | -11% | 38% |
| 23 | 7% | 0% | -19% | 22% | 12% | -17% | 6% | -9% | 70% | -1% | 10% | 12% | 90% |
| 22 | -32% | 6% | 12% | -7% | -16% | 10% | 4% | -2% | 3% | -6% | -3% | 3% | -29% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and cushing's disease; and CRN09682, a nonpeptide drug conjugate for SST2 positive solid tumors. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease; and SST3 Agonist program for the treatment of polycystic kidney disease, as well as Oral GLP-1 and Oral GIP nonpeptides for the treatment of obesity. The company has an agreement with Sanwa Kagaku Kenkyusho Co., Ltd to develop and commercialize Paltusotine in Japan, and Cellular Longevity, Inc. to develop and commercialize CRN01941, a somatostatin receptor type 2 agonist. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$3.88B
P/E ratio
—
52W high
$57.99
52W low
$25.83
Volume
7,02,431
Beta
0.28
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Crinetics Pharmaceuticals, Inc. share price today?
- Crinetics Pharmaceuticals, Inc. (CRNX) last traded around $36.80 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does CRNX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for CRNX. Download the app for real-time alerts.
- How can I analyze Crinetics Pharmaceuticals, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.